Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4
| Parent link: | Human Psychopharmacology: Clinical and Experimental Vol. 35, iss. 4.— 2020.— [e2737, 8 p.] |
|---|---|
| Korporativní autor: | |
| Další autoři: | , , , , , , , , |
| Shrnutí: | Title screen Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic?induced HPRL. Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the ?2 test. Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (?2 = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]). |
| Jazyk: | angličtina |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/hup.2737 |
| Médium: | Elektronický zdroj Kapitola |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=662600 |